Compare CCHH & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCHH | CTSO |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.6M | 23.9M |
| IPO Year | 2025 | 2008 |
| Metric | CCHH | CTSO |
|---|---|---|
| Price | $1.21 | $6.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 37.6K | ★ 392.3K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,503,908.00 |
| Revenue This Year | N/A | $10.34 |
| Revenue Next Year | N/A | $22.41 |
| P/E Ratio | $43.55 | ★ N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $0.18 | $0.30 |
| 52 Week High | $15.39 | $7.44 |
| Indicator | CCHH | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 41.97 | 90.86 |
| Support Level | $1.17 | $0.48 |
| Resistance Level | $1.34 | N/A |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | -0.02 | 0.72 |
| Stochastic Oscillator | 0.00 | 85.76 |
CCH Holdings Ltd, through its subsidiaries, operates a specialty hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot. The Group offers catering services in Malaysia and outside Malaysia, mainly under two brands, namely Chicken Claypot House for its chicken hotpot restaurants and Zi Wei Yuan for its fish head hotpot restaurants. It operates or licenses several restaurant outlets, among which include Chicken Claypot House, Zi Wei Yuan, 888 Family Food Courts, and other outlets under the Bibixian, Banbudian Bistro, and Chao Liu Xian Hotpot brands. A large share of its restaurants are located in Malaysia, with additional franchised outlets in Thailand, Indonesia, and China. Geographically, the Group's revenues are all derived from Malaysia.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.